###### Strengths and limitations of this study

-   This systematic review is the first to describe variation in outcomes, outcome measurement instruments and outcome measurement time reporting in clinical trials for non-valvular atrial fibrillation (NVAF).

-   The methodology is reproducible and transparent and has been assessed during a peer-review process.

-   English and Chinese databases were searched, and randomised controlled trials and observational studies were considered.

-   The aim of this review was to provide a list of outcomes for clinical trials of NVAF in traditional Chinese medicine, which is focused on Chinese herbal medicine therapy. Thus, clinical trials of surgery were not considered.

Introduction {#s1}
============

According to a systematic review, atrial fibrillation (AF) is the main contributor to many diseases, such as ischaemic heart disease, stroke, renal disease and peripheral arterial disease. In addition, AF usually results in major cardiovascular events, cardiovascular and all-cause mortality, and sudden cardiac death.[@R1] Thus, treating AF is important.

There are different kinds of classifications for AF. According to the aetiology, AF can be classified as isolated AF, valvular AF, non-valvular AF (NVAF) and so on. NVAF refers to AF occurring without rheumatic mitral stenosis, mechanical/bioprosthetic or mitral valve repair.[@R2] According to the characteristics and timing of AF onset, AF can be classified as first diagnosed AF, paroxysmal AF, persistent AF, long-standing persistent AF and permanent AF.[@R3]

Current evidence has shown that catheter ablation and drug therapy are beneficial for controlling heart rhythm, maintaining ventricular rate, and preventing thrombosis and stroke. However, the arrhythmogenic effects and risk of death after taking antiarrhythmic drugs cannot be ignored. With the increasing number of traditional Chinese medicine (TCM) clinical trials in treating AF, the efficacy and safety of TCM have been proven.[@R4] However, there are some problems in these TCM clinical trials; for example, similar clinical trials reported different outcomes. Therefore, some trials cannot be included in systematic reviews/meta-analyses because of outcome reporting heterogeneity. In TCM clinical trials, the long-term outcomes, patient-reported outcomes and safety outcome reporting are limited; thus, these trials cannot provide appropriate evidence for TCM in treating AF. Developing a core outcome set (COS) may resolve these problems.

A COS is a minimum set that should be measured and reported in all clinical trials for a specific condition.[@R5] According to the characteristics and advantages of TCM, we intend to develop a COS for TCM clinical trials for NVAF, with registered[@R6] and published[@R7] protocols.

According to the study protocol, conducting a systematic review is the first step in the development of a COS for NVAF to develop a long list of outcomes. In this research, we will report the results of the systematic review, including assessing the quality of outcome reporting and the quality of trials, as well as examining the variation in outcome reporting, outcome measurement instrument (OMI) reporting and measurement time point reporting.

Methods {#s2}
=======

Search strategy {#s2-1}
---------------

In clinical trials and clinical practice, TCM, especially Chinese herbal medicine therapy is often used as an adjuvant therapy in internal medicine treatment; thus, obtaining a comprehensive list of outcomes for TCM clinical trials is difficult. In this systematic review, we focused on clinical trials of TCM, integrated medicine and Western medicine in internal medicine. The literature database included PubMed, the Cochrane Library, Web of Science, Wanfang database, the China National Knowledge Infrastructure and SinoMed. A literature search was conducted two times. The first search was conducted from January 2015 to June 2017, and the second search was conducted from May 2017 to March 2019. The search strategy for English databases is shown in [online supplementary additional file 1](#SP1){ref-type="supplementary-material"}.
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Inclusion criteria {#s2-2}
------------------

According to the protocol, both randomised controlled trials (RCTs) and observational studies were considered. Patients with NVAF who accepted interventions including TCM or Western medicines were eligible. The required treatment duration or follow-up time was ≥4 weeks. For RCTs, the required number of participants was ≥30 in each group. For observational studies, the required number of participants was ≥50.

Exclusion criteria {#s2-3}
------------------

We excluded clinical trials that aimed to investigate the outcome of complications of NVAF, to assess the mechanism of drug action or pharmacokinetics, or for which full text could not be acquired.

Methodological quality has little influence on developing a long list of outcomes in the development of a COS. However, we excluded some studies with serious problems, such as a Jadad score of 0 for RCTs, contradictions in the research or the authors are in the institutions who do not have the ability to conduct RCTs in China.

Study identification {#s2-4}
--------------------

Two reviewers (RQ and SH) independently assessed the titles and abstracts from searches. Then, the full texts of the potential articles were retrieved and assessed for further identification. Any disagreement was resolved by discussion or consulting the third investigator (HS).

Data extraction {#s2-5}
---------------

Two reviewers (RQ and JH) independently extracted information. The information included the first author's name, publication time, number of participants, country of authors (if the authors are from different countries, it was stated as 'international'), interventions, comparisons, course of treatment, follow-up duration, outcomes, the definition of outcomes, OMIs and measurement time (intervention duration or follow-up time). Any disagreement was resolved by discussion or consulting the third investigator (HS).

In addition, we assessed the quality of outcome reporting according to the method used in other studies.[@R8] There were six items; if the information of eligible studies completely meet the items, then 1 point was awarded. If this information did not meet or fully meet the items, then 0 point was awarded. If the outcome was objective, then the definition is unnecessary.

The items include the following:

1.  Is the primary outcome clearly stated?

2.  Is the primary outcome clearly defined so that another researcher would be able to reproduce its measurement? Where appropriate, this outcome should include a clear description of time points, the person measuring the outcome, how the outcome was measured (for example, tools and methods used) and where the outcome was measured.

3.  Are the secondary outcomes clearly stated?

4.  Are the secondary outcomes clearly defined?

5.  Do the authors explain the use of the outcomes they have selected?

6.  Are methods used to enhance the quality of outcome measurement (for example, repeated measurement, training) if appropriate?

The methodological quality was assessed according to the type of study. The Jadad score was used to assess the quality of RCTs,[@R10] and the Newcastle-Ottawa Scale was used to assess the quality of cohort studies (CoSs).[@R11] The tool developed by Canadian Institute of Health Economics can be used to assess the quality of case series studies.[@R12]

Two reviewers (RQ and JH) independently assessed the quality of outcome reporting and the methodological quality. Any disagreement was resolved by discussion or consulting the third investigator (HS).

Merging outcomes and grouping under outcome domains {#s2-6}
---------------------------------------------------

Two researchers (RQ and CZ) merged the overlapping outcomes according to the definition of outcomes independently. If no definition was provided, they discussed and achieved consensus if necessary. For example, death, death from any cause, mortality, overall mortality, total mortality, all causes of death and all causes of mortality were aggregated as 'all-cause mortality'.

The original list of outcomes from systematic review is usually very long and unwieldy,[@R13] so researchers developed a taxonomy for outcome classification[@R14] that included 38 outcome domains. Two researchers (RQ and CZ) grouped individual outcomes into the appropriate outcome domain together and achieved consensus.

Statistical analysis {#s2-7}
--------------------

The results were analysed by descriptive analysis.

Patient and public involvement {#s2-8}
------------------------------

Patients and the public were not involved in the design or planning of the study. Patients will be involved in the larger study to develop the COS. Informed consent will be obtained from patients who will participate in the later research.

Results {#s3}
=======

Characteristics of literature {#s3-1}
-----------------------------

In this systematic review, a total of 25 255 articles from Chinese and English databases were retrieved. After removing duplicates, there were 17 240 articles. By reading the titles and abstracts, ineligible articles were removed, and full texts for 1233 potential eligible articles were retrieved. A total of 1015 articles were removed for various reasons, and 218 articles were finally included. The flowchart of this systematic review is shown in [figure 1](#F1){ref-type="fig"}.

![The flowchart of the systematic review.](bmjopen-2018-028803f01){#F1}

In the included studies, 88 studies were for antiarrhythmic therapy, and 130 studies were for anticoagulant therapy. A total of 110 articles were in Chinese, and 108 articles were in English. Thirty articles were TCM clinical trials, and 188 were Western medicine clinical trials. Seventy-five articles were observational studies (including 66 CoS and 9 case series), while 143 articles were RCTs. The general characteristics of the included articles are shown in [table 1](#T1){ref-type="table"}.

###### 

The characteristics of included articles

  Study ID                               Study type   Country         Patients recruited   Course of treatment   Follow-up duration      Quality of outcome reporting   Quality of study   Interventions                                                 Comparisons
  -------------------------------------- ------------ --------------- -------------------- --------------------- ----------------------- ------------------------------ ------------------ ------------------------------------------------------------- ----------------------------------------------------------
  Kang[@R17]                             RCT          China           98                   1 Year                /                       2                              2/5                Triple antithrombotic therapy+CT                              Dual antithrombotic therapy+CT
  Guo *et al* [@R18]                     RCT          China           62                   /                     1 Year                  2                              2/5                Atorvastatin+CT                                               CT
  Li *e* *t al* [@R19]                   RCT          China           76                   8--10 Days            6 Months                0                              2/5                Amiodarone+dabigatran                                         Warfarin
  Bu *et al* [@R20]                      RCT          China           192                  /                     1 Year                  2                              3/5                Low-dose warfarin                                             Normal-dose warfarin
  Pan and Liu[@R21]                      RCT          China           90                   6 Months              /                       0                              3/5                Candesartan+rosuvastatin                                      CT+candesartan
  Li[@R22]                               RCT          China           80                   4 Weeks               1 Year                  2                              2/5                Dabigatran+CT                                                 Warfarin+CT
  Chen *et al* [@R23]                    RCT          China           80                   /                     1 Year                  2                              2/5                Warfarin+CT                                                   Aspirin+CT
  Sang *e* *t al* [@R24]                 RCT          China           80                   /                     1 Year                  2                              2/5                Valsartan+rosuvastatin+CT                                     CT
  Guo[@R25]                              RCT          China           60                   1 Month               6 Months                2                              2/5                Amiodarone+irbesartan                                         Amiodarone
  Zuo *et al* [@R26]                     RCT          China           180                  /                     3 Months                2                              3/5                Dabigatran                                                    Warfarin
  Liu, *et al* [@R27]                    RCT          China           140                  /                     1 Year                  0                              2/5                Dabigatran                                                    Warfarin
  Yang [@R28]                            RCT          China           120                  /                     1 Year                  0                              2/5                Amlodipine+amiodarone                                         Candesartan+amiodarone
  Li *et al* [@R29]                      RCT          China           60                   3 Months              /                       0                              2/5                Candesartan+amiodarone                                        Amiodarone
  Yang *et al* [@R30]                    RCT          China           88                   2 Months              /                       0                              3/5                Sotalol+irbesartan                                            Sotalol
  Li *et al* [@R31]                      CoS          China           74                   4 Weeks               /                       0                              5/9                Valsartan                                                     Hydrochlorothiazide
  Lin *et al* [@R32]                     RCT          China           120                  6 Months              6 Months                2                              2/5                Rosuvastatin+CT                                               CT
  Qin *et al* [@R33]                     RCT          China           360                  /                     2 Years                 0                              2/5                Warfarin                                                      Aspirin
  Qin *et al* [@R34]                     RCT          China           360                  /                     2 Years                 0                              2/5                Low-dose warfarin                                             High-dose warfarin; aspirin
  Chen *et al* [@R35]                    RCT          China           77                   1 Year                /                       0                              2/5                Dabigatran+clopidogrel                                        Warfarin
  Wang *et al* [@R36]                    RCT          China           150                  /                     1 Year                  3                              2/5                Aspirin+warfarin                                              Aspirin; warfarin
  Liu and Zhang[@R37]                    RCT          China           150                  3 Months--1 year      /                       0                              2/5                Low-dose warfarin                                             High-dos-e warfarin; aspirin
  Zhang[@R38]                            RCT          China           118                  /                     1 Year                  0                              2/5                Irbesartan+CT                                                 Irbesartan
  Zhang[@R39]                            RCT          China           120                  /                     30 Days                 0                              2/5                Amiodarone                                                    Propafenone
  Huang *et al* [@R40]                   RCT          China           76                   1 Year                /                       2                              2/5                Irbesartan+amiodarone+CT                                      Amiodarone+CT
  Xu *et al* [@R41]                      RCT          China           234                  /                     2 Years                 0                              2/5                Aspirin                                                       Low-dose warfarin; high-dose warfarin
  Lin[@R42]                              RCT          China           158                  /                     10 Months               0                              2/5                Candesartan+amiodarone+CT                                     Amiodarone+CT
  Zhang and Zong[@R43]                   RCT          China           62                   /                     3 Months                0                              2/5                High-dose warfarin                                            Normal-dose warfarin
  Guo[@R44]                              RCT          China           100                  1 Year                /                       0                              2/5                Amiodarone+irbesartan                                         Amiodarone+metoprolol
  Zhang[@R45]                            RCT          China           160                  1 Year                /                       0                              3/5                Indapamide+valsartan+CT                                       Valsartan+CT
  Yang and Yao[@R46]                     RCT          China           150                  3 Months              /                       0                              3/5                Methimazole+bisoprol+CT                                       Bisoprol+CT
  Zhang and Gu [@R47]                    RCT          China           70                   /                     3 Months                0                              2/5                Amiodarone +CT                                                Amiodarone+deacetyl glucoside
  Hou and Liu[@R48]                      RCT          China           136                  1 Year                /                       0                              2/5                Amiodarone+irbesartan                                         Amiodarone
  Jiang and Xu[@R49]                     RCT          China           70                   4 Weeks               11 Months               0                              2/5                Valsartan+amiodarone+CT                                       Amiodarone+CT
  Song *et al* [@R50]                    RCT          China           120                  1 Year                /                       0                              3/5                Amiodarone+fosinopril                                         Amiodarone
  Wang and Yuan[@R51]                    RCT          China           76                   4 Weeks               /                       0                              2/5                Bisoprol+CT                                                   Amiodarone+CT
  Yan et al[@R52]                        RCT          China           96                   /                     2 Years                 0                              2/5                Propafenone+CT                                                Amiodarone+CT
  Zhang and Yin[@R53]                    RCT          China           92                   1 Year                /                       2                              2/5                Irbesartan+amiodarone                                         Amlodipine+amiodarone
  Jian[@R54]                             RCT          China           68                   /                     3 Months                0                              2/5                Warfarin                                                      Aspirin
  Huang and Qin6[@R55]                   RCT          China           60                   /                     2 Years                 0                              2/5                Dabigatran                                                    Warfarin
  Yang[@R56]                             RCT          China           180                  1 Year                /                       2                              3/5                Rosuvastatin+amiodarone+CT                                    Amiodarone+CT
  Liu *et al* [@R57]                     RCT          China           91                   /                     2 Years                 2                              2/5                Moderate-dose warfarin                                        Low-dose warfarin
  Zhou *e* *t al* [@R58]                 RCT          China           120                  6 Months              /                       0                              3/5                High-dose atorvastatin                                        Low-dose atorvastatin
  Chen[@R59]                             RCT          China           96                   6 Months              /                       0                              3/5                Enalapril+amiodarone                                          Amiodarone
  Wang and Jin[@R60]                     RCT          China           176                  6 Months              /                       0                              3/5                High-dos-e rosuvastatin                                       Normal-dose rosuvastatin
  Ou *et al* [@R61]                      RCT          China           88                   /                     6 Months                0                              2/5                Atorvastatin+CT                                               CT
  Geng *et al* [@R62]                    RCT          China           198                  /                     10--20 mMonths          0                              2/5                Aspirin+dipyridamole                                          Aspirin
  Chu[@R63]                              RCT          China           90                   1 Year                /                       0                              2/5                Amiodarone+benapril                                           Amiodarone
  Zhu[@R64]                              RCT          China           86                   3 Months              /                       0                              2/5                Candesartan+amiodarone                                        Amiodarone
  Lin[@R65]                              RCT          China           90                   1 Year                /                       0                              3/5                Amiodarone+telmisartan                                        Amiodarone
  Duan *et al* [@R66]                    RCT          China           80                   /                     1 Year                  0                              2/5                Amiodarone+spironolactone                                     Amiodarone
  Lu *et al* [@R67]                      RCT          China           64                   /                     2 Months                0                              3/5                Dabigatran                                                    Warfarin
  Wei and Li[@R68]                       RCT          China           120                  6 Months              /                       2                              2/5                High-dose dabigatran +warfarin                                Low-dose dabigatran+warfarin
  Su *et al* [@R69]                      RCT          China           74                   /                     6 Months                0                              3/5                Amiodarone                                                    Cedilanid
  Yu[@R70]                               RCT          China           82                   12 Weels              /                       2                              3/5                Irbesartan+amiodarone                                         Amiodarone
  Li *et al* [@R71]                      RCT          China           108                  1 Year                /                       2                              2/5                Perindopril+amiodarone+CT                                     CT
  Wen[@R72]                              RCT          China           80                   /                     2 Years                 0                              2/5                Low-dose aspirin                                              High-dose aspirin
  Chen[@R73]                             RCT          China           200                  /                     1 Year                  2                              2/5                Low-dose warfarin                                             High-dose warfarin
  Xu *et al* [@R74]                      RCT          China           200                  /                     1 Year                  0                              2/5                Metoprolol; metoprolol+spironolactone; metoprolol+valsartan   No treatment
  Huang *et al* [@R75]                   RCT          China           153                  1 Year                /                       2                              3/5                Rosuvastatin+amiodarone + CT                                  Amiodarone+CT
  Zhao and Dong[@R76]                    RCT          China           98                   1 Year                /                       0                              3/5                Atorvastatin+CT                                               CT
  Feng *et al* [@R77]                    RCT          China           64                   4 Weeks               /                       0                              2/5                Maixuekang+warfarin+CT                                        CT+warfarin
  Bo *et al* [@R78]                      RCT          China           160                  1 Month               6 Months                2                              2/5                Amiodarone+wenxin granule                                     Amiodarone
  Zhang and Peng[@R79]                   RCT          China           80                   30 Days               /                       2                              3/5                CT+modified Buuyang huanwu decoction                          CT
  Chen *et al* [@R80]                    RCT          China           60                   3 Months              /                       2                              2/5                Jianxin pinglv pill+warfarin+metoprolol                       Warfarin+metoprolol
  Cao *et al* [@R81]                     RCT          China           220                  4 Weeks               /                       2                              3/5                CT+shensong yangxin capsule                                   CT
  Chang and Zhou[@R82]                   RCT          China           88                   8 Weeks               /                       2                              3/5                Atorvastatin+wenxin granule+CT                                CT+amiodarone
  Fan[@R83]                              RCT          China           112                  6 Months              /                       0                              1/5                Losartan+amiodarone +shensong yangxin capsule                 Losartan+amiodarone
  Ye[@R84]                               RCT          China           80                   4 Weeks               /                       0                              2/5                Wenxin granule+propafenone                                    Propafenone
  Wang[@R85]                             RCT          China           60                   3 Months              /                       0                              2/5                Taoren honghua decoction+warfarin                             Warfarin
  Cheng *et al* [@R86]                   RCT          China           200                  180 Days              /                       0                              3/5                Yangxin guicao decoction+CT                                   CT
  Han et al[@R87]                        RCT          China           60                   4 Weeks               /                       2                              3/5                Xifeng Zhiji decoction+metoprolol                             Metoprolol
  Peng[@R88]                             RCT          China           96                   1 Year                /                       0                              2/5                CT+Amiodarone+shexiang baoxin pill                            CT+amiodarone
  Zhang[@R89]                            RCT          China           180                  12 Weeks              /                       2                              2/5                Wenxin granule+CT                                             CT
  Pan *et al* [@R90]                     RCT          China           65                   3 Months              /                       0                              2/5                Amiodarone+jianxin pinglv pill                                Amiodarone
  Huang[@R91]                            RCT          China           120                  1 Year                /                       0                              2/5                CT+valsartan+dabuyuan decoction                               CT+valsartan
  Li *et al* [@R92]                      RCT          China           90                   1 Month               /                       0                              3/5                Shensong yangxin capsule+Amiodarone + CT                      Amiodarone+CT
  Wang and Wang[@R93]                    RCT          China           72                   3 Months              /                       0                              3/5                Wenxin granule+CT                                             CT
  Cui[@R94]                              RCT          China           80                   8 Weeks               /                       2                              2/5                Zhigancao decoction+metoprolol                                Metoprolol
  Bi[@R95]                               RCT          China           70                   8 Weeks               /                       0                              3/5                Dingxin granule                                               Amiodarone
  Zhang[@R96]                            RCT          China           116                  24 Weeks              /                       0                              3/5                Shensong yangxin capsule+CT                                   CT
  Chen *et al* [@R97]                    RCT          China           60                   4 Weeks               /                       2                              3/5                Zhigancao decoction+amiodarone                                Amiodarone
  Liu *et al* [@R98]                     RCT          China           68                   4 Weeks               /                       2                              2/5                Dingxin granule+metoprolol                                    Metoprolol
  Zhang[@R99]                            RCT          China           84                   6 Months              /                       0                              1/5                CT+amiodarone+wenxin granule                                  CT+amiodarone
  Granger *e* *t al* [@R100]             RCT          International   13 397               1--4 Years            /                       4                              3/5                Apixaban                                                      Warfarin
  Held *et al* [@R101]                   RCT          International   18 201               1--4 Years            /                       4                              3/5                Apixaban                                                      Warfarin
  Jaspers et al[@R102]                   RCT          International   18 201               1--4 Years            30 Months\*             5                              3/5                Apixaban                                                      Warfarin
  Bahit *et al* [@R103]                  RCT          International   18 140               1--4 Years            /                       2                              3/5                Edoxaban                                                      Warfarin
  Alexander *e* *t al* [@R104]           RCT          International   17 370               1--4 Years            1.8 Years†              2                              3/5                Higher-dose edoxaban; lower-dose edoxaban                     Warfarin
  Hu *e* *t al* [@R105]                  RCT          International   18 201               1--4 Years            1 Year                  4                              3/5                Aapixaban                                                     Warfarin
  Pengo *e* *t al* [@R106]               RCT          Italy           180                  /                     ≥30 Days                2                              3/5                Pharmacogenetic warfarin dosing                               Standard warfarin dosing
  Steffel *e* *t al* [@R107]             RCT          International   2492                 907 Days†             2.8 Years†              1                              5/5                Edoxaban                                                      Warfarin
  Yamashita *e* *t al* [@R108]           RCT          International   1943                 907 Days†             2.8 Years†              6                              5/5                Warfarin                                                      Edoxaban
  Kato *e* *t al* [@R109]                RCT          International   21 105               907 Days†             2.8 Years†              4                              5/5                Higher-dose edoxaban; lower-dose edoxaban                     Warfarin
  Meng *e* *t al* [@R110]                RCT          China           180                  /                     12 Months               3                              3/5                Wenxin granule                                                Sotalol
  Wang *e* *t al* [@R111]                RCT          China           151                  1 Year                1 Year                  4                              3/5                Aspirin+naoxintong capsule                                    Warfarin
  Brambatti *e* *t al* [@R112]           RCT          USA             18 113               /                     2 Years                 3                              5/5                Dabigatran                                                    Warfarin
  Verdecchia *e* *t al* [@R113]          RCT          USA             10 372               /                     2 Years                 3                              5/5                Dabigatran                                                    Warfarin
  Tan *e* *t al* [@R114]                 RCT          China           126                  /                     2 Years                 2                              5/5                Fluvastati                                                    Placebo
  Shah *e* *t al* [@R115]                RCT          International   5205                 1 Year                668 Days†               2                              3/5                Aspirin                                                       Rivaroxaban
  Sun *e* *t al* [@R116]                 RCT          International   14 236               1 Year                668 Days†               2                              3/5                Rivaroxaban                                                   Warfarin
  Yao *e* *t al* [@R117]                 RCT          China           92                   1 Year                /                       0                              3/5                Fluvastatin+benazepril                                        Fluvastatin
  Goette *e* *t al* [@R118]              RCT.         International   2199                 28 Days               30 Days                 4                              3/5                Edoxaban                                                      Enoxaparin-warfarin
  Magnani *e* *t al* [@R119]             RCT          International   14 071               907 Days              2.8 Years               5                              5/5                Edoxaban                                                      Warfarin
  Senoo *e* *t al* [@R120]               RCT          UK              4556                 /                     11.6 Months             3                              3/5                SR34006                                                       Warfarin or acenocoumarol
  Hijazi *e* *t al* [@R121]              RCT          International   16 869               1 Year                /                       4                              3/5                Apixaban                                                      Warfarin
  Cadrin *e* *t al* [@R122]              RCT          Canada          1376                 /                     37 Months†              3                              4/5                Rhythm control                                                Rate control therapy
  Maciag *e* *t al* [@R123]              RCT          Poland          74                   /                     /                       5                              4/5                Antazoline                                                    Control
  Ng *e* *t al* [@R124]                  RCT          International   5599                 /                     1.1 Years               4                              4/5                Apixaban                                                      Acetylsalicylic acid
  Inoue *e* *t al* [@R125]               RCT          Japan           127                  2 Weeks               /                       5                              3/5                5 mg fixed dose β-Blockers                                    10 mg dose-escalation group; 20 mg dose-escalation group
  Dong *e* *t al* [@R126]                RCT          China           79                   /                     19.84 Months†           2                              2/5                Intravenous ibutilide                                         Intravenous amiodarone+Intravenous ibutilide
  Hong *e* *t al* [@R127]                RCT          South Korea     183                  4 Weeks               7 Days                  4                              5/5                Rivaroxaban                                                   Warfarin sodium
  Tan *e* *t al* [@R128]                 RCT          China           118                  2 Years               /                       2                              2/5                Fluvastatin+CT                                                CT
  Zhang *e* *t al* [@R129]               RCT          China           120                  1 Year                /                       0                              2/5                CT+low-dose rosuvastatin; CT+high-dose rosuvastatin           CT
  Zhou *e* *t al* [@R130]                RCT          China           186                  6 Months              /                       2                              3/5                Telmisartan                                                   Non-ARB and non-ACEI
  Qian *e* *t al* [@R131]                RCT          China           85                   4 Weeks               /                       0                              3/5                TCM+CT                                                        CT
  Di *e* *t al* [@R132]                  RCT          China           50                   6 Months              /                       3                              2/5                Telmisartan+amiodarone                                        Amiodarone
  Liu [@R133]                            RCT          China           200                  2 Months              /                       0                              3/5                Valsartan                                                     Nifedipine
  Yu *e* *t al* [@R134]                  RCT          China           146                  /                     1 Year                  2                              2/5                Amiodarone +rosuvastatin+valsartan                            Amiodarone+valsartan
  Zhang and Jiao[@R135]                  RCT          China           158                  /                     1--2 Years              2                              2/5                Warfarin+CGA                                                  Warfarin
  Li *e* *t al* [@R136]                  RCT          China           120                  1 Year                /                       0                              1/5                Telmisartan+CT                                                Amlodipine+CT
  Pang *e* *t al* [@R137]                RCT          China           60                   6 Months              /                       2                              2/5                Valsartan                                                     Amlodipine
  Wang [@R138]                           RCT          China           126                  12 Weeks              /                       2                              3/5                Atorvastatin+irbesartan+CT                                    Irbesartan+CT
  Yan *e* *t al* [@R139]                 RCT          China           124                  1 Year                /                       0                              3/5                Benapril+amiodarone+CT                                        Amiodarone+CT
  Huang *e* *t al* [@R140]               RCT          China           125                  6 Months              /                       2                              2/5                Valsartan+CT                                                  Nifedipine+CT
  Yuan and Liu[@R141]                    RCT          China           92                   1 Year                /                       2                              2/5                Candesartan+CT                                                CT
  Chen *e* *t al* [@R142]                RCT          China           102                  /                     1 Year                  2                              2/5                Rivaroxaban                                                   Warfarin
  Tu[@R143]                              RCT          China           124                  /                     1 Year                  0                              2/5                Warfarin                                                      Aspirin
  Bassand *e* *t al* [@R144]             CoS          International   17 162               /                     2 Years                 0                              7/9                Antithrombotic treatment                                      
  Haas *e* *t al* [@R145]                CoS          International   9934                 /                     1 Year                  0                              7/9                VKAs                                                          
  Chan *e* *t al* [@R146]                CoS          China           571                  /                     2.6 Years\*             4                              5/9                Dabigatran                                                    Warfarin
  Chan *e* *t al* [@R147]                CoS          China           2153                 /                     4.2 Years\*             4                              6/9                Dabigatran                                                    Warfarin
  Xie *e* *t al* [@R148]                 CoS          USA             127 068              /                     30 days                 2                              7/9                Apixaban                                                      Warfarin
  Bengtson *e* *t al* [@R149]            CoS          USA             61 648               /                     15 Months†              4                              5/9                Dabigatran; rivaroxaban                                       Warfarin
  Chan *e* *t al*2016[@R150]             CS           China           115                  /                     4 Weeks                 4                              14/20              Warfarin; aspirin; or dabigatran                              
  Hohnloser *e* *t al* [@R151]           CoS          Germany         35 013               /                     218--280 Days           4                              5/9                Phenprocoumon; anticoagulants                                 
  Saji *e* *t al* [@R152]                CoS          Japan           235                  /                     30 Days                 2                              7/9                NOACs                                                         Warfarin
  Korenstra *e* *t al* [@R153]           CoS          Netherlands     920                  /                     2 Years                 5                              8/9                Dabigatran                                                    Acenocoumarol
  Naganuma *e* *t al* [@R154]            CoS          Japan           362                  /                     1.3 Years               3                              8/9                Dabigatran                                                    Warfarin
  Sunbul *e* *t al* [@R155]              CoS          Turkey          171                  /                     1 Year                  2                              7/9                Coumadin; dabigatran;rivaroxaban                              
  Yao *e* *t al* [@R156]                 CoS          USA             76 354               /                     0.5--0.7 Year\*         3                              4/9                Dabigatran; rivaroxaban; apixaban                             Warfarin
  Ezekowitz *e* *t al* [@R157]           RCT          USA             5851                 /                     4.6 Years†              3                              5/5                Dabigatran 150 mg                                             Dabigatran 110 mg
  Camm *e* *t al* [@R158]                CS           UK              6785                 /                     1 Year                  5                              17/20              Rivaroxaban                                                   
  Marquez-Contreras *e* *t al* [@R159]   CS           Spain           412                  /                     1 Year                  2                              14/20              Rivaroxaban                                                   
  Tepper *e* *t al* [@R160]              CoS          USA             45 338               /                     1.1 Years†              1                              9/9                Warfarin                                                      
  Li *e* *t al* [@R161]                  CoS          USA             76 940               /                     1 Year                  2                              8/9                Warfarin                                                      Apixaban
  Marquez *e* *t al* [@R162]             CS           Spain           412                  /                     1 Year                  2                              14/20              Rivaroxaban                                                   
  Larsen *e* *t al* [@R163]              CoS          Denmark         61 678               /                     2.5 Years               2                              6/9                Non-vitamin K antagonist oral anticoagulants                  Warfarin
  Kilickiran *e* *t al* [@R164]          CoS          Turkey          294                  280--336 days         /                       3                              6/9                Dabigatran                                                    Rivaroxaban
  Inoue *e* *t al* [@R165]               CoS          Japan           6148                 /                     2 Years                 2                              4/9                Dabigatran                                                    
  Chan *e* *t al* [@R166]                CoS          China           5426                 /                     3.6 Years\*             2                              5/9                Warfarin                                                      Aspirin; no therapy
  Laliberte *e* *t al* [@R167]           CoS          Canada          13 049               /                     114 and 123.7 Days\*    3                              4/9                Rivaroxaban                                                   Warfarin
  Lee *e* *t al* [@R168]                 CoS          Korea           321                  /                     2.3 Months\*            3                              6/9                VKAs                                                          
  Lau *e* *t al* [@R169]                 CoS          China           8152                 /                     501 Days\*              0                              6/9                Dabigatran                                                    Warfarin
  Ho *e* *t al* [@R170]                  CoS          China           8754                 /                     3 Years\*               4                              5/9                Aspirin                                                       Dabigatran; warfarin
  Chan *e* *t al* [@R171]                CoS          China           9727                 /                     2Yyears                 2                              7/9                Warfarin                                                      Aspirin
  Chao *e* *t al* [@R172]                CoS          China           101 243              /                     4.9 Years\*             0                              7/9                Betablockers                                                  Calcium channel blockers; digoxin
  Pastori *e* *t al* [@R173]             CoS          Italy           815                  /                     33.2 Months†            2                              6/9                Digoxin                                                       
  Chen *e* *t al* [@R174]                CoS          China           10 384               /                     3.2 Years               2                              6/9                Anticoagulation and antiplatelet therapy                      
  Engelberger *e* *t al* [@R175]         CoS          Switzerland     537                  /                     3 Months                4                              5/9                Rivaroxaban                                                   
  Li *e* *t al* [@R176]                  RCT          China           137                  /                     1 Year                  0                              2/5                Low-dose warfarin                                             Unclear
  Tung *et al* [@R177]                   CS           Canada          148 446              /                     5 Years                 1                              10/20              Warfarin                                                      
  Wu *et al* [@R178]                     CoS          China           4638                 /                     2.4 Years†              4                              8/9                Statin                                                        Non-statin
  Kodani *et al* [@R179]                 CoS          Japan           6616                 /                     5 Years                 1                              6/9                Warfarin; NOACs                                               No anticoagulation therapy
  Yamashita *et al* [@R180]              CoS          Japan           6404                 /                     2 Years                 0                              7/9                Warfarin                                                      
  Kumagai *et al* [@R181]                CoS          Japan           6404                 /                     2 Years                 0                              7/9                Warfarin+statin                                               Warfarin alone
  Blin *et al* [@R182]                   CoS          France          8894                 /                     28--29 Months           2                              8/9                VKAs:                                                         
  Piccini *et al* [@R183]                CoS          USA             10 135               /                     2.3Years†               0                              5/9                Unclear                                                       
  Allen *et al* [@R184]                  CoS          USA             9619                 /                     22 Months\*             3                              7/9                Digoxin                                                       
  Genovesi *et al* [@R185]               CoS          Italy           290                  /                     2 Years                 0                              7/9                Warfarin                                                      
  Qin *et al* [@R186]                    CoS          USA             5952                 /                     26.1 Months             4                              7/9                Antiarrhythmic drugs                                          
  Purmah *et al* [@R187]                 CoS          International   3119                 /                     1 Year                  2                              7/9                Rate control                                                  Rhythm control
  Pasca *et al* [@R188]                  CS           Italy           143                  /                     1 Year                  2                              15/20              Oral anticoagulant therapy                                    No oral anticoagulant therapy
  Nielsen *et al* [@R189]                CoS          Denmark         55 644               /                     2.3 Years\*             1                              8/9                NOACs                                                         Warfarin
  Bo *et al* [@R190]                     CoS          Italy           452                  /                     300.5 Days\*            2                              7/9                Oral anticoagulant therapy                                    No oral anticoagulant therapy
  Jacobs *et al* [@R191]                 CoS          USA             5254                 /                     243 Days\*              2                              7/9                DOACs                                                         Warfarin
  Lip *et al* [@R192]                    CoS          International   29 338               /                     90--127 Days            2                              8/9                Warfarin                                                      Apixaban, dabigatran or rivaroxaban.
  Hanon *et al* [@R193]                  CS           France          405                  /                     6 Months                4                              14/20              Rivaroxaban                                                   
  Patti *et al* [@R194]                  CoS          International   6412                 /                     1 Year                  2                              8/9                Antithrombotic therapies                                      
  Graham *et al* [@R195]                 CoS          USA             118 891              /                     108 and 111 Days\*      4                              6/9                Dabigatran                                                    Rivaroxaban
  Tampieri *et al* [@R196]               CS           Italy           218                  /                     30 Days                 1                              15/20              Anticoagulation                                               
  Lee *et al* [@R197]                    CoS          South Korea     754                  /                     3.2--3.5 years\*        2                              7/9                VKAs                                                          No vitamin K antagonist
  Stolk *et al* [@R198]                  CoS          Netherlands     30 146               /                     1--3 Years              2                              5/9                DOACs; VKAs; low-dose aspirin or mixed users                  
  Boriani *et al* [@R199]                CoS          International   2589                 /                     1 Year                  2                              7/9                According to AF type                                          
  Eisen *et al* [@R200]                  RCT          International   21 105               907 Days^\#^          2.8 Years^\#^           3                              7/9                Digoxin                                                       No Digoxin
  Wan and Deng[@R201]                    RCT          China           292                  3 Months              3 Months                0                              2/5                Dabigatran+clopidogrel                                        Clopidogrel
  Jian [@R202]                           RCT          China           128                  3 Months              /                       0                              2/5                Dabigatran+CT                                                 Warfarin+CT
  Gao [@R203]                            RCT          China           71                   /                     1 Year                  0                              3/5                Low-dose warfarin                                             Normal-dose warfarin
  Wang [@R204]                           RCT          China           84                   /                     1 Year                  0                              3/5                Warfarin                                                      Warfarin
  DM Zhang and HM Zhang [@R205]          RCT          China           81                   /                     1 Year                  0                              2/5                Warfarin                                                      Warfarin
  Haqingaowa *et al* [@R206]             RCT          China           146                  6 Months              /                       2                              3/5                Rivaroxaban+CT                                                Warfarin+CT
  Chen *et al* [@R207]                   RCT          China           86                   1 Year                /                       2                              3/5                Rivaroxaban+CT                                                Warfarin+CT
  Chen *et al* [@R208]                   RCT          China           160                  /                     6 Months                2                              1/5                Maixuekang capsule                                            Aspirin
  Li and Yue[@R209]                      RCT          China           76                   4 Weeks               /                       0                              3/5                TCM+dabigatran+aspirin                                        Dabigatran+aspirin
  Yu [@R210]                             RCT          China           80                   4 Weeks               /                       0                              2/5                Xuefu Zhuyu decoction+dabigatran                              Dabigatran
  RR *e* *t al* [@R211]                  RCT          International   245                  /                     1 Year                  5                              5/5                Targeted therapy+CT                                           CT
  Ezekowitz *e* *t al* [@R212]           RCT          International   1500                 /                     30 and 90 Days\*        2                              3/5                Apixaban                                                      Heparin/VKA
  Li X *e* *t al* [@R213]                RCT          China           66                   /                     6 Months                1                              2/5                Genotype-based anticoagulant therapy with warfarin            Routine warfarin therapy
  Yamashita *e* *t al* [@R214]           RCT          Japan           220                  4 weeks               /                       4                              2/5                Bisoprolol transdermal patch                                  Bisoprolol fumarate oral formulation
  Bartlett *e* *t al* [@R215]            CoS          USA             286                  12.4 months†          16.5 Months^†^          6                              7/9                Rivaroxaban with concomitant diltiazem                        Rivaroxaban
  Andersson *e* *t al* [@R216]           CoS          Denmark         9212                 /                     1 Year                  2                              8/9                Dabigatran                                                    Warfarin
  Deitelzweig *e* *t al* [@R217]         CoS          USA             25 857               /                     5--6 Months†            1                              8/9                Apixaban                                                      Rivaroxaban, dabigatran, warfarin
  Friberg and Oldgren[@R218]             CoS          Sweden          68 056               /                     0.71 and 1.74 Years†    3                              8/9                NOAC                                                          Warfarin
  Hernandez *e* *t al* [@R219]           CoS          USA             41 336               /                     185--294 Days\*         5                              8/9                Apixaban;dabigatran; rivaroxaban; warfarin                    Never used oral anticoagulation
  Pohjantahti *e* *t al* [@R220]         CoS          Finland         200                  /                     1 Year                  6                              7/9                Vernakalant                                                   Flecainide
  Koretsune *e* *t al* [@R221]           CoS          Japan           18 261               /                     1 Year                  5                              8/9                Dabigatran                                                    Warfarin
  Lai *e* *t al* [@R222]                 CoS          China           2592                 /                     3.86--4.95 Years\*      3                              8/9                Amiodarone; amiodarone+digoxin                                Digoxin
  Li WH *e* *t al* [@R223]               CoS          China           2099                 /                     21.7 Months\*           6                              8/9                Warfarin                                                      Rivaroxaban; dabigatran
  Link *e* *t al* [@R224]                CoS          International   21 099               907 Days\*            1022 Days†              5                              7/9                Warfarin                                                      High-dose edoxaban; low-dose edoxaban
  Lip *e* *t al* [@R225]                 CoS          Denmark         14 020               /                     2.6 Years\*             3                              8/9                Apixaban; dabigatran; rivaroxaban                             Warfarin
  Noseworthy *e* *t al* [@R226]          CoS          USA             107 373              /                     3 Years                 2                              8/9                Warfarin                                                      Apixaban; dabigatran; rivaroxaban
  Lip *e* *t al* [@R227]                 CoS          USA             321 182              /                     1 Year                  4                              8/9                Apixaban; warfarin; dabigatran; rivaroxaban                   
  Martinez *e* *t al* [@R228]            CoS          The USA         6836                 /                     1.4 Years†              3                              8/9                Rivaroxaban                                                   Warfarin
  Gieling *e* *t al* [@R229]             CoS          The UK          31 497               /                     0.95--2.94 Years\*      6                              8/9                NOACs; VKA; aspirin; mixed                                    
  Go *e* *t al* [@R230]                  CoS          The USA         50 578               66 Days†              102--123 Days\*         3                              8/9                Dabigatran                                                    Warfarin
  Forslund *e* *t al* [@R231]            CoS          Sweden          22 198               /                     1.07 and 1.61 Years\*   6                              8/9                Dabigatran; rivaroxaban; apixaban                             Warfarin
  Sjalander *e* *t al* [@R232]           CoS          Sweden          64 382               208--407 Days\*       /                       3                              8/9                Dabigatran; rivaroxaban; apixaban                             Warfarin
  Corbalan *e* *t al* [@R233]            CoS          International   21 105               /                     2.8 Years               5                              8/9                Edoxaban                                                      Warfarin
  Bae *e* *t al* [@R234]                 CS           Korea           1350                 /                     3 Years                 3                              16/20              Non-VKA                                                       VKA

\*Mean follow-up.

†Median follow-up.

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin Ⅱ receptor antagonist; CGA, comprehensive geriatric assessment; CS, case series; CT, conventional therapy; CoS, cohort study; DOACs, direct oral anticoagulants; NOACs, non-vitamin K antagonist oral anticoagulants; TCM, traditional Chinese medicine; VKAs, vitamin K antagonists.

The majority of RCTs were conducted in China. The USA had more CoSs than other countries did ([figure 2](#F2){ref-type="fig"}). Because of the limited information provided in the articles, 35.32% (77/218) of the studies received 0 points for the quality of outcome reporting, and the majority were RCTs ([figure 3](#F3){ref-type="fig"}). Compared with other countries, China had a much lower quality of outcome reporting ([figure 4](#F4){ref-type="fig"}). The majority of RCTs were poor quality, while the majority of observational studies were high quality.

![The type and distribution of clinical trials.](bmjopen-2018-028803f02){#F2}

![The quality of outcome reporting in different types of clinical trials.](bmjopen-2018-028803f03){#F3}

![The quality of outcome reporting in different countries.](bmjopen-2018-028803f04){#F4}

The list of outcomes {#s3-2}
--------------------

There are two main types of therapy for NVAF: antiarrhythmic treatment and anticoagulation treatment. Some differences exist in the outcome reporting between these therapies. This review shows the outcomes according to the type of interventions in the original study.

For clinical trials of antiarrhythmic therapy, 69 outcomes from 16 outcome domains were reported ([table 2](#T2){ref-type="table"}). Twenty-eight (31.82%, 28/88) outcomes were reported only once; the most frequently reported outcome was ultrasonic cardiogram, which was reported 39 times (44.32%, 39/88). None of the outcomes were reported more than 50 times. In the 16 outcome domains, 5 outcome domains (vascular outcomes, adherence/compliance, adverse events/effects; physical functioning; withdrawal from treatment) consisted of only one outcome. These outcomes were reported between 1 and 26 times, and the median outcome reporting time was 1. Cardiac outcomes consisted of the largest number of outcomes, including 22 outcomes. In cardiac outcomes, ultrasonic cardiogram (39 times), AF recurrence (36 times), conversion to sinus rhythm (26 times), heart rate (21 times) and blood pressure (20 times) were reported much more often than other outcomes.

###### 

The outcomes reporting for clinical trials of antiarrhythmic treatment (N=88)

  Domains/outcomes                                   Outcomes reporting (n)   OMIs/definitions (n)   Measurement time point (n)
  -------------------------------------------------- ------------------------ ---------------------- ----------------------------
  Mortality/survival                                                                                 
   All-cause mortality                               11                       0                      8
   Cardiovascular death                              5                        0                      3
  Vascular outcomes                                                                                  
   Non-central nervous system embolism               6                        0                      2
  Cardiac outcomes                                                                                   
   ECG outcomes                                      18                       2                      14
   Time to conversion                                7                        1                      5
   Mean sinus rhythm maintenance time                1                        1                      6
   Time to first AF recurrence                       4                        1                      3
   Conversion to sinus rhythm                        26                       1                      12
   Sinus rhythm maintenance                          15                       3                      6
   AF recurrence                                     36                       2                      2
   AF progression                                    6                        2                      3
   AF controlling rate                               2                        0                      2
   AF persistence                                    11                       2                      5
   Number of electrical cardioversion                1                        0                      1
   Number of taking antiarrhythmic drugs             1                        0                      1
   Number of undertaking ablation                    1                        0                      1
   Ultrasonic cardiogram                             39                       1                      10
   Heart rate                                        21                       2                      14
   NYHA classification grading of cardiac function   3                        1                      2
   Myocardial infarction                             2                        0                      2
   Bradycardia                                       1                        0                      0
   Ventricular arrhythmia                            2                        1                      1
   Heart failure                                     2                        0                      2
   Blood pressure                                    20                       0                      6
   NT-proBNP                                         3                        0                      3
  Blood and lymphatic system outcomes                                                                
   D-dimer                                           2                        0                      2
   APTT                                              1                        0                      1
   TT                                                1                        0                      1
   PT                                                1                        0                      1
   FIB                                               3                        1                      3
  Nervous system outcomes                                                                            
   Haemorrhagic stroke                               11                       0                      6
   Ischaemic stroke                                  6                        0                      4
  Immune system outcomes                                                                             
   IFN-γ                                             1                        0                      1
   IL-10                                             1                        0                      1
   IL-4                                              1                        0                      1
   IL-6                                              10                       1                      4
   TNF-α                                             9                        1                      4
   MMP2                                              4                        1                      3
   Solubility P-selectin                             1                        1                      1
   Connective tissue growth factor                   1                        1                      1
   TIMP2                                             1                        1                      1
  Endocrine outcomes                                                                                 
   Aldosterone                                       1                        0                      1
   ANP                                               1                        1                      1
   TSH                                               2                        0                      1
   Renin, AngII                                      4                        1                      1
   Adiponectin                                       1                        1                      1
  Hepatobiliary outcomes                                                                             
   ALT                                               1                        0                      3
   AST                                               1                        0                      3
  Renal and urinary outcomes                                                                         
   BUN                                               6                        1                      3
   Serum creatinine                                  1                        0                      3
   Urine sodium                                      1                        0                      1
  Metabolism and nutrition outcomes                                                                  
   HDL-C                                             3                        0                      4
   LDL-C                                             7                        1                      4
   TC                                                6                        0                      4
   TG                                                5                        0                      4
   Serum homocysteine                                3                        1                      3
  General outcomes                                                                                   
   Body mass index                                   1                        0                      1
   Mean drug onset time                              1                        0                      1
   Symptoms                                          9                        2                      7
   CRP                                               6                        1                      5
   hs-CRP                                            12                       2                      4
  Adherence/compliance                                                                               
   Therapeutic compliance                            1                        0                      5
  Withdrawal from treatment                                                                          
   Withdrawal from treatment                         1                        0                      1
  Physical functioning                                                                               
   6 Min walk test                                   1                        1                      1
  Adverse events/effects                                                                             
   Adverse events/side effects                       26                       0                      8
  Resource use: Hospital                                                                             
   All-cause hospitalisation                         5                        0                      3
   Cardiovascular hospitalisations                   6                        1                      4
   Hospital length of stay                           1                        0                      0
   Readmission rates                                 1                        0                      1

ALT, alanine aminotransferase; ANP, atrial natriuretic peptide;APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C reactive protein; ECG, electrocardiogram; FIB, fibrinogen; HDL-C, High density lipoprotein cholesterol; IFN-γ, interferon-γ; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; MMP2, matrix metalloproteinase-2; NT-proBNP, N terminal pro B type natriuretic peptide; NYHA, New York Heart Association; PT, prothrombin time; TC, total cholesterol; TG, total triglyceride; TIMP2, tissue inhibitor of metalloproteinase 2; TNF-α, tumour necrosis factor-α; TSH, thyroid stimulating hormone; TT, thrombin time.

For clinical trials of anticoagulation therapy, there were 82 outcomes from 18 outcome domains in the studies of anticoagulation therapy ([table 3](#T3){ref-type="table"}). Thirty-eight (29.23%, 38/130) outcomes were reported only once; the most frequently reported outcome was ischaemic stroke, which was reported 105 times (80.77%, 105/130). Only 5 (3.85%, 5/130) outcomes were reported more than 50 times. In the 18 outcome domains of anticoagulation therapy studies, 5 outcome domains (satisfaction/patient preference, withdrawal from treatment, global quality of life, economic and adverse events/effects) consisted of only one outcome. These outcomes were reported between 1 and 16 times, and the median outcome reporting time was 3. Blood and lymphatic system outcomes included the largest number of outcomes, which was 14 outcomes; the international normalised ratio (INR) was reported more frequently than other outcomes.

###### 

The outcomes reporting for clinical trials of anticoagulant treatment (N=130)

  Domains/outcomes                                                                 Outcomes reporting (n)   OMIs/definitions (n)   Measurement time point (n)
  -------------------------------------------------------------------------------- ------------------------ ---------------------- ----------------------------
  Mortality/survival                                                                                                               
   All-cause mortality                                                             52                       2                      40
   Cardiovascular death                                                            26                       2                      13
   Death from ischaemic events                                                     3                        0                      1
   Death from stroke                                                               1                        1                      1
   Death from bleeding                                                             1                        0                      1
   Non-cardiovascular death                                                        1                        0                      1
  Vascular outcomes                                                                                                                
   Non-central nervous system embolism                                             73                       1                      31
   Major bleeding                                                                  75                       10                     42
   Time to first major bleeding event                                              2                        0                      3
   Minor bleeding                                                                  21                       2                      8
   Clinically relevant non-major bleeding                                          15                       4                      5
   Time to first clinically relevant non-major bleeding event                      1                        0                      2
   Time to the first SEE                                                           2                        0                      1
  Cardiac outcomes                                                                                                                 
   Acute coronary syndrome                                                         31                       0                      27
   Ultrasonic cardiogram                                                           1                        1                      1
   Blood pressure                                                                  1                        0                      1
   Heart failure                                                                   1                        0                      1
   NT-proBNP                                                                       2                        1                      3
  Blood and lymphatic system outcomes                                                                                              
   INR                                                                             17                       1                      7
   Prothrombin time                                                                8                        1                      5
   APTT                                                                            8                        1                      5
   PT                                                                              10                       2                      6
   TT                                                                              5                        1                      5
   FIB                                                                             4                        1                      3
   Thrombin time                                                                   5                        1                      4
   Time spent in the therapeutic range                                             5                        0                      3
   PLT                                                                             2                        0                      2
   RBC                                                                             1                        0                      1
   HGB                                                                             1                        0                      1
   D-dimer                                                                         3                        0                      3
   Haemorheology                                                                   1                        1                      1
   Thromboela-stogram                                                              1                        1                      1
   Plasma P selectin                                                               1                        1                      1
   TXB2                                                                            1                        1                      1
  Nervous system outcomes                                                                                                          
   Ischaemic stroke                                                                105                      2                      56
   Haemorrhagic stroke                                                             75                       2                      39
   Transient ischaemic attack                                                      18                       0                      10
   Intracranial bleeding                                                           14                       2                      11
   Time to the first stroke                                                        3                        0                      2
   Score standard of neural function deficient degree                              1                        1                      1
   Dementia                                                                        1                        0                      1
  Hepatobiliary outcomes                                                                                                           
   ALT                                                                             2                        0                      2
   AST                                                                             2                        0                      2
   TBIL                                                                            1                        0                      1
  Renal and urinary outcomes                                                                                                       
   Serum creatinine                                                                1                        1                      1
   Glomerular filtration rate                                                      1                        0                      1
   BUN                                                                             1                        1                      1
   Creatinine clearance                                                            1                        0                      1
   Carbamide                                                                       1                        0                      1
   β~2~-microglobulin                                                              1                        1                      1
  Musculoskeletal and connective tissue outcomes                                                                                   
   Hip fracture                                                                    2                        0                      1
   Pelvic fracture                                                                 1                        0                      1
   Vertebral fracture                                                              1                        0                      1
  General outcomes                                                                                                                 
   Symptoms                                                                        3                        0                      3
   Warfarin dosage                                                                 2                        0                      1
   INR variance growth rate                                                        1                        1                      1
   Time to stable anticoagulation                                                  1                        0                      1
   Weight                                                                          1                        0                      1
   Traditional Chinese medicine syndrome                                           2                        1                      2
   CRP                                                                             1                        0                      1
   CGA score                                                                       1                        1                      2
  Physical functioning                                                                                                             
   Modified Rankin Scale score                                                     1                        1                      1
   Disability                                                                      1                        0                      1
  Satisfaction/patient preference                                                                                                  
   Patient satisfaction                                                            3                        3                      4
  Adherence/compliance                                                                                                             
   Therapeutic compliance                                                          11                       0                      9
   Anticoagulation discontinuation                                                 3                        1                      8
  Withdrawal from treatment                                                                                                        
   Withdrawal from treatment                                                       1                        1                      2
  Global quality of life                                                                                                           
   Quality of life                                                                 4                        5                      4
  Economic                                                                                                                         
   Index hospitalisation costs                                                     1                        1                      1
  Resource use: Hospital                                                                                                           
   Admission for cerebrovascular event                                             7                        3                      5
   All-cause hospitalisation                                                       4                        0                      2
   Cardiovascular hospitalisation                                                  4                        0                      1
   Hospital length of stay                                                         3                        1                      1
   Bleeding-cause hospitalisation                                                  2                        0                      3
   Healthcare resource utilisation                                                 2                        1                      1
   Emergency room visits                                                           1                        0                      10
   Readmission rates                                                               2                        1                      11
  Need for further intervention                                                                                                    
   The difference between the predicted and the actual warfarin maintenance dose   1                        0                      1
   The number of warfarin dose changes needed                                      1                        0                      1
   First catheter ablation                                                         1                        0                      1
   First AV node/His bundle ablation                                               1                        0                      1
  Adverse events/effects                                                                                                           
   Adverse events/effects                                                          16                       0                      7

ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AV, atrioventricular; BUN, blood urea nitrogen; CGA, comprehensive geriatric assessment; CRP, C reactive protein; FIB, fibrinogen; HGB, haemoglobin; INR, international normalised ratio; NT-proBNP, N terminal pro B type natriuretic peptide; PLT, platelet; PT, prothrombin time; RBC, red blood cell; SEE, systemic embolic event; TBIL, total bilirubin; TT, thrombin time; TXB2, thromboxane B2.

There were 24 duplicated outcomes between antiarrhythmic therapy and anticoagulation therapy. After removing duplicates, there were 127 outcomes. [Figure 5](#F5){ref-type="fig"} shows a summary of outcomes reporting times. [Figure 6](#F6){ref-type="fig"} shows the number of outcomes in different outcome domains in antiarrhythmic treatment trials. [Figure 7](#F7){ref-type="fig"} shows the number of outcomes in different outcome domains in anticoagulation treatment trials.

![The summary of outcome reporting times.](bmjopen-2018-028803f05){#F5}

![The number of outcomes in different outcome domains in antiarrhythmic treatment trials.](bmjopen-2018-028803f06){#F6}

![The number of outcomes in different outcome domains in anticoagulant treatment trials.](bmjopen-2018-028803f07){#F7}

A large number of clinical trials did not provide definitions or OMIs. In the outcomes of antiarrhythmic treatment trials, 31 outcomes (44.93%, 31/69) were provided definitions or OMIs. Twenty-three (33.33%, 23/69) outcomes were provided one OMI or definition, seven (10.14%, 7/69) outcomes were provided two OMIs or definitions and one (1.45%, 1/69) outcome was provided three OMIs or definitions. Sinus rhythm maintenance had three different OMIs or definitions, which was higher than that of other outcomes. In the outcomes of anticoagulant therapy trials, 40 (48.78%, 40/82) were provided OMIs or definitions. Twenty-eight (35.37%, 28/82) outcomes were provided one OMI or definition, seven (8.54%, 7/82) outcomes were provided two OMIs or definitions and five (6.10%, 5/82) outcomes were provided three or more OMIs or definitions. Major bleeding had more definitions than other outcomes did.

In addition, there were many different measurement times for the same outcome. In the clinical trials of antiarrhythmic treatment, the outcome measurement times ranged from 1 to -14 times, and the median time was 3.Forty-three outcomes (62.32%, 43/69) had two or more measurement times. Heart rate and ECG outcomes had more measurement times than other outcomes did. In clinical trials of anticoagulant therapy, the outcome measurement times ranged from 1 to 56, with a median of 1.5; among these outcomes 41(50.00%, 41/82) had two or more measurement times. In addition, ischaemic stroke had more measurement times than other outcomes did.

Discussion {#s4}
==========

This systematic review is the first to evaluate the quality of outcome reporting of clinical trials of TCM and western medicine for treating NVAF. The results showed variations in the outcome reporting, OMIs/outcome definitions and outcome measurement time reporting in different clinical trials. These problems may result in the exclusion of some studies from systematic reviews/meta-analyses due to the heterogeneity of outcomes or outcome measurements; thus, these studies cannot provide a higher level of evidence for clinical practice.

In clinical trials for NVAF, investment wastes also exist because approximately 1/3 of outcomes were reported only once in included trials of anticoagulation therapy and antiarrhythmic therapy. For example, conversion to sinus rhythm, which is important to the results of clinical trials of antiarrhythmic therapy, was reported by 29.55% (26/88) of articles. Some long-term outcomes, such as all-cause mortality and cardiovascular deaths, were reported in 12.50% (11/88) and 5.68% (5/88) of articles, respectively.

In addition, adverse events/effects were inadequately reported. In clinical trials of anticoagulant therapy, safety outcomes such as haemorrhage were grouped under vascular outcomes according to the degree of bleeding (such as major bleeding, clinically relevant non-major bleeding and minor bleeding). Then, only 12.31% (16/130) of the included articles reported other kinds of adverse events/effects. For clinical trials of antiarrhythmic therapy, only 29.55% (26/88) of the included articles reported adverse events/effects.

For all of the outcomes in the list, patient' perspectives could not be identified sufficiently. For example, among all of the included 88 articles for antiarrhythmic therapy, none of them reported quality of life, while in all of the included 130 articles for anticoagulant therapy, only 4 of them reported quality of life.

There were 30 articles for clinical trials of TCM. TCM syndrome, which could reflect the characteristics of TCM, was reported only two times. A few other articles reported symptoms related to TCM syndrome. This phenomenon cannot reflect the characteristics and advantages of TCM.

After assessing the quality of outcome reporting and studies, the results showed that the majority of included trials had poor quality. Although the poor quality of studies may not influence the result of developing a long list of outcomes, the poor quality of outcome reporting made it difficult to extract sufficient information from the articles. The reasons for poor quality of studies and outcome reporting may be because most studies in China do not follow the Consolidated Standards of Reporting Trials (CONSORT) statement or observational studies reporting items. Moreover, the majority of journals in Chinese do not require studies to follow the CONSORT statement; thus, some studies provided limited information on key methodological issues. In addition, Chinese researchers prefer to report comprehensive outcomes rather than individual outcomes, and studies have reported only primary outcomes.

Only a small number of included studies provided OMIs or definitions, which made it difficult to assess the quality of outcome measures. Additionally, the variation in OMIs or definitions can make it impossible to conduct meta-analyses. In addition, selecting OMIs with good measurement properties is very important after developing a COS[@R15] to ensure that reliability, validity and ethical standards are achieved.

The measurement time was much shorter in Chinese journals than in English journals. In general, long-term outcomes were usually reported in observational studies, while short-term outcomes were usually reported in RCTs. It is a challenge for a single trial to measure all of these outcomes in a meaningful way, especially an outcome such as mortality, which requires longer follow-up and a larger sample size.[@R16] Therefore, recommending measurement times for different outcomes is important.

Developing a COS for NVAF may reduce the heterogeneity of outcome reporting in different clinical trials, so that clinical trials can be included in systematic reviews/meta-analyses to provide a higher quality of evidence for clinical practice. Moreover, if the majority of clinical trials can be included in systematic review, it may help reduce investment wastes. Reviewers can easily determine if publication bias is present when a COS is used. For TCM clinical trials, a COS may help improve the quality of studies if researchers report consensus outcomes, which may help improve the development of TCM.
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